CIAN HEALTHCARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.8 INR | +0.19% |
|
-1.89% | +21.85% |
| 2023 | Cian Healthcare to Supply 13 Pharmaceutical Products for HLL Lifecare | MT |
| 2023 | Cian Healthcare Limited Reports Earnings Results for the Half Year Ended September 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 781M 9.38M | Sales 2023 | 687M 8.25M | Capitalization | 700M 8.41M |
|---|---|---|---|---|---|
| Net income 2022 | -55M -661K | Net income 2023 | 20M 240K | EV / Sales 2022 | 1.4 x |
| Net Debt 2022 | 617M 7.41M | Net Debt 2023 | 595M 7.15M | EV / Sales 2023 | 1.88 x |
| P/E ratio 2022 |
-8.21
x | P/E ratio 2023 |
34.6
x | Employees | 275 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.8% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.19% | ||
| 1 week | -1.89% | ||
| Current month | +1.27% | ||
| 1 month | -2.85% | ||
| 3 months | -10.15% | ||
| 6 months | -1.28% | ||
| Current year | +21.85% |
1 week
20.44
21.92
1 month
20.3023.60
Current year
16.0524.20
1 year
16.0541.10
3 years
12.0041.10
5 years
10.2562.90
10 years
10.2562.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | - | |
| Director of Finance/CFO | 39 | 08-10-31 | |
| Chairman | 49 | 03-01-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 49 | 03-01-06 | |
| Director of Finance/CFO | 39 | 08-10-31 | |
Paresh Arun Shah
BRD | Director/Board Member | 44 | 19-07-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 20.8 | +0.19% | 4,000 |
| 24-05-16 | 20.76 | -0.81% | 16,000 |
| 24-05-15 | 20.93 | -1.46% | 26,000 |
| 24-05-14 | 21.24 | +0.28% | 14,000 |
| 24-05-13 | 21.18 | -0.09% | 18,000 |
Delayed Quote Bombay S.E., May 17, 2024 at 06:00 am EDT
More quotes
Cian Healthcare Limited is an India-based company, which is engaged in the manufacturing and marketing of pharmaceutical products. The Company is engaged in manufacturing of multiple lines-tablets, capsules, soft gels, liquid orals, ointments/ creams and sachets, cosmetics. The Company operates in five sectors, such as Export, Government Supplies, Merchant Export, Own Brand Franchise Business and Third Party/ Contract manufacturing. Its portfolio comprises gynecology, haematinic, cardio- diabetic, orthopedic, pediatric, derma-cosmetic, and antibiotic, CNS, vitamin and nutrient products. The Company also exports its product to various countries, such as Afghanistan, Benin, Bhutan, Bolivia, Cambodia, Sri Lanka, Myanmar and also enhances its production capacity by installing additional machinery for manufacturing a variety of products. It is also engaged in the business of manufacturing cosmetic products. The Company's subsidiary includes Dr. Smith Biotech Private Limited.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +21.85% | 6.24M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.89% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- CHCL Stock
